Yttrium-90 Microspheres: A review of its emerging clinical indications

Liver Cancer

Volumn 4, Issue 1, 2015, Pages 6-15

  Khajornjiraphan, Natthida ^a   Thu, Nyein Aye ^a   Chow, Pierce Kah Hoe ^a,b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Cancer; Emerging indications; Treatment; Yttrium 90

Indexed keywords

ANTINEOPLASTIC AGENT; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG;

BILE DUCT CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL EFFECTIVENESS; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION INJURY; RADIOEMBOLIZATION; REVIEW; SARCOMA; SYSTEMIC THERAPY; TREATMENT INDICATION; UTERINE CERVIX CANCER;

EID: 84945135854     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000343876     Document Type: Review

References (56)

1. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010;25:657-663.
2. Hung H: Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005;5:131-138.
3. Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 2012;1:71-82.
4. Mise Y, Sakamoto Y, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, Sugawara Y, Kokudo N: A worldwide survey of the current daily practice in liver surgery. Liver Cancer 2013;2:55-66.
5. Cheah YL, Chow PK: Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer 2012;1:183-189.
6. Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013;2:73-83.
7. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41-50.
8. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
9. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
10. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H: Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011;34:422-431.
11. ClinicalTrials.gov: Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer (SORAMIC). 2014 [cited 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01126645?term=soramic&rank=1.
12. Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC, Asia-Pacific Hepatocellular Carcinoma Trials Group: Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS ONE 2014;9:e90909.
13. Gil-Alzugaray B, Chopitea A, Iarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, Benito A, Dominguez I, DAvola D, Herrero JI, Quiroga J, Prieto J, Sangro B: Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013;57:1078-1087.
14. Lewandowski RJ, Geschwind JF, Liapi E, Salem R: Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-657.
15. SIRTEX: Approved Indication. About SIR-Spheres microspheres 2014 [cited 2014 14/03/2014]; Available from: http://www.sirtex.com/us/clinicians/about-sir-spheres-microspheres/approved-indication/.
16. Bester L, Meteling B, Pocock N, Saxena A, Chua TC, Morris DL: Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J Med Imaging Radiat Oncol 2013;57:72-80.
17. Bester L, Feitelson S, Milner B, Chua TC, Morris DL: Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors. Am J Clin Oncol 2013:37(5):454-60.
18. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines KG 3rd, Salem R: Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572-586.
19. Gulec SA, Pennington K, Wheeler J, Barot TC, Suthar RR, Hall M, Schwartzentruber D: Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Am J Clin Oncol 2013;36:455-460.
20. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL: Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010;251:910-916.
21. Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, Metreweli C, Johnson P, Li AK: Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994-999.
22. Razumilava, N. and G.J. Gores, Cholangiocarcinoma. Lancet, 2014.
23. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD: Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-762.
24. Kim JH, Won HJ, Shin YM, Kim KA, Kim PN: Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011;196:205-209.
25. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R: Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012;24:437-443.
26. Saxena A, Bester L, Chua TC, Chu FC, Morris DL: Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484-491.
27. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, Kim HS: Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440-448.
28. Hoffmann RT, Paprottka PM, Schn A, Bamberg F, Haug A, Drr EM, Rauch B, Trumm CT, Jakobs TF, Helmberger TK, Reiser MF, Kolligs FT: Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105-116.
29. Haug AR, Heinemann V, Bruns CJ, Hoffmann R, Jakobs T, Bartenstein P, Hacker M: 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 2011;38:1037-1045.
30. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A 3rd, Omary RA, Salem R: Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008;113:2119-2128.
31. Turkmen C, Ucar A, Poyanli A, Vatankulu B, Ozkan G, Basaran M, Serin K, Sanli Y, Adalet I: Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm 2013;28:534-540.
32. el-Domeiri AA, Huvos AG, Goldsmith HS, Foote FW Jr: Primary malignant tumors of the liver. Cancer 1971;27:7-11.
33. Weitz J, Klimstra DS, Cymes K, Jarnagin WR, DAngelica M, La Quaglia MP, Fong Y, Brennan MF, Blumgart LH, Dematteo RP: Management of primary liver sarcomas. Cancer 2007;109:1391-1396.
34. Matthaei H, Krieg A, Schmelzle M, Boelke E, Poremba C, Rogiers X, Knoefel WT, Peiper M: Long-term survival after surgery for primary hepatic sarcoma in adults. Arch Surg 2009;144:339-344, discussion 344.
35. Oh JC, et al: Y-90 radioembolization of primary and metastatic soft tissue sarcomas of the liver. J Vasc Interv Radiol 2013;24(Suppl):S148 Abs.342.
36. Saxena A, Kapoor J, Meteling B, Morris DL, Bester L: Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol 2014;21:1296-1303.
37. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A: Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol 2012;35:167-177.
38. Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Reiser MF, Helmberger TK: Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008;19:683-690.
39. Cianni R, Pelle G, Notarianni E, Saltarelli A, Rabuffi P, Bagni O, Filippi L, Cortesi E: Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013;23:182-189.
40. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N: Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012;10:354-362.
41. Bujold A, Dawson LA: Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. Cancer Radiother 2011;15:54-63.
42. Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, Budgeon CA, Boucek JA, Francis RJ, Cheo TS, Burgmans MC, Irani FG, Lo RH, Tay KH, Tan BS, Chow PK, Satchithanantham S, Tan AE, Ng DC, Goh AS: Post-radioembolization yttrium-90 PET/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res 2013;3:57.
43. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A, Technology Assessment Committee Interventional Oncology Task Force of the Society of Interventional Radiology: Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-278.
44. Gulec SA, Pennington K, Hall M, Fong Y: Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 2009;7:6 Epub 2009/01/10.
45. Cao C, Yan TD, Morris DL, Bester L: Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. Tumori 2010;96:955-958.
46. Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, Boeck S, Haas M, Laubender RP, Heinemann V: Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology 2014;86:24-32.
47. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K: Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol 2003;20:25-28.
48. Eldridge L: Lung Cancer Spread to the Liver. September 12, 2013; Available from: http://lungcancer.about. com/od/lungcancermetastases/a/Lung-Cancer-Liver.htm.
49. Murthy R, Mutha P, Lee JH, Oh Y: Yttrium-90-labeled microsphere radioembolotherapy of liver-dominant metastases from thoracic malignancies. J Vasc Interv Radiol 2008;19:299-300.
50. Gaba RC, Lakhoo J: Yttrium-90 microsphere radioembolization for treatment of lung cancer hepatic metastases. Case Rep Oncol 2012;5:479-486.
51. Ricke J, Groer O, Amthauer H: Y90-radioembolization of lung metastases via the bronchial artery: a report of 2 cases. Cardiovasc Intervent Radiol 2013;36:1664-1669.
52. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP: Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007;25:1099-1106.
53. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B: Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85.
54. Weintraub JL, Salem R: Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol 2013;24:1123-1134.
55. ClinicalTrials.gov: Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC). 2014 [cited 2014; Available from: http://clinicaltrials.gov/ct2/show/study/NCT01556490?term=NCT01 556490&rank=1..
56. ClinicalTrials.gov: Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB). 2014 [cited 2014; Available from: http://clinicaltrials.gov/ct2/show/NCT01135056?term=NCT01135056&ra nk=1..